1. Home
  2. MAIA vs WYY Comparison

MAIA vs WYY Comparison

Compare MAIA & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • WYY
  • Stock Information
  • Founded
  • MAIA 2018
  • WYY 1991
  • Country
  • MAIA United States
  • WYY United States
  • Employees
  • MAIA N/A
  • WYY N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • WYY EDP Services
  • Sector
  • MAIA Health Care
  • WYY Technology
  • Exchange
  • MAIA Nasdaq
  • WYY Nasdaq
  • Market Cap
  • MAIA 56.3M
  • WYY 55.2M
  • IPO Year
  • MAIA 2022
  • WYY 1998
  • Fundamental
  • Price
  • MAIA $1.61
  • WYY $5.38
  • Analyst Decision
  • MAIA
  • WYY Strong Buy
  • Analyst Count
  • MAIA 0
  • WYY 2
  • Target Price
  • MAIA N/A
  • WYY $7.50
  • AVG Volume (30 Days)
  • MAIA 468.7K
  • WYY 86.3K
  • Earning Date
  • MAIA 11-11-2025
  • WYY 11-12-2025
  • Dividend Yield
  • MAIA N/A
  • WYY N/A
  • EPS Growth
  • MAIA N/A
  • WYY N/A
  • EPS
  • MAIA N/A
  • WYY N/A
  • Revenue
  • MAIA N/A
  • WYY $144,421,640.00
  • Revenue This Year
  • MAIA N/A
  • WYY $9.19
  • Revenue Next Year
  • MAIA N/A
  • WYY $13.16
  • P/E Ratio
  • MAIA N/A
  • WYY N/A
  • Revenue Growth
  • MAIA N/A
  • WYY 16.25
  • 52 Week Low
  • MAIA $1.40
  • WYY $2.19
  • 52 Week High
  • MAIA $3.48
  • WYY $6.25
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 50.48
  • WYY 69.05
  • Support Level
  • MAIA $1.54
  • WYY $5.26
  • Resistance Level
  • MAIA $1.78
  • WYY $5.40
  • Average True Range (ATR)
  • MAIA 0.09
  • WYY 0.30
  • MACD
  • MAIA 0.02
  • WYY 0.02
  • Stochastic Oscillator
  • MAIA 45.31
  • WYY 73.57

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: